Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$11.69 USD

11.69
3,365,285

+3.39 (40.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $11.84 +0.15 (1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -4.76% and 2.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -33.33% and 94.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

by Zacks Equity Research

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -9.09% and 59.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Philips (PHG) Showcases New AI-Based Solutions at the RSNA

by Zacks Equity Research

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -142.98% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed at $2.51 in the latest trading session, marking a -1.57% move from the prior day.

Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.

Agenus (AGEN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Agenus (AGEN) closed at $2.63, marking a +0.77% move from the previous day.

Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed the most recent trading day at $2.61, moving -1.14% from the previous trading session.

Agenus (AGEN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed at $2.72 in the latest trading session, marking a +1.49% move from the prior day.

VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study

by Zacks Equity Research

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

Agenus (AGEN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed at $2.65 in the latest trading session, marking a -1.12% move from the prior day.

Here's Why You Should Invest in Vertex (VRTX) Stock Now

by Zacks Equity Research

Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Agenus (AGEN) Stock Moves -0.49%: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed the most recent trading day at $2.05, moving -0.49% from the previous trading session.

Here is What to Know Beyond Why Agenus Inc. (AGEN) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.

Ekta Bagri headshot

Bet on These 4 Biotech Stocks With Bright Prospects

by Ekta Bagri

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication

by Zacks Equity Research

AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.

Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris

by Zacks Equity Research

Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States

Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Agenus (AGEN) closed at $2.31, marking a -1.28% move from the previous day.

Philips (PHG) to Showcase New Innovations & Cardiac Solutions

by Zacks Equity Research

Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.

AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID

by Zacks Equity Research

CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.

Is Trending Stock Agenus Inc. (AGEN) a Buy Now?

by Zacks Equity Research

Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.